Nitric oxide: State of the art in drug design

Current Medicinal Chemistry

Volumn 19, Issue 3, 2012, Pages 386-405

  Serafim, R A M ^a   Primi, M C ^a   Trossini, G H G ^a   Ferreira, E I ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biochemical pathways; Drug design; Hybrid compounds; Immune system; Medicinal chemistry; Mutual prodrugs; Nitric oxide; Nitric oxide synthase inhibitors; NO releasing agents; Therapeutic potential

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTINEOPLASTIC AGENT; ARC 102222; CAPTOPRIL; CYCLOOXYGENASE 2 INHIBITOR; DEOXYURIDINE DERIVATIVE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSORBIDE MONONITRATE; LATANOPROST; LOSARTAN; NCX 1021; NCX 125; NCX 139; NCX 201; NCX 278; NCX 4040; NCX 434; NCX 6550; NCX 6553; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PRAZOSIN; PROPRANOLOL; S NITROSOTHIOL; SARTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANGINA PECTORIS; ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIFUNGAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; COUGHING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; EXCITATION CONTRACTION COUPLING; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HUMAN; HYDROPHOBICITY; HYPERTENSION; IMMUNE RESPONSE; INTRAOCULAR HYPERTENSION; NEUROTRANSMISSION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATIC DISEASE; SLOW DRUG RELEASE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASOCONSTRICTION; VASODILATATION;

EID: 84857716998     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803414321     Document Type: Article

References (166)

1. Kerwin, J. F.; Lancaster, J. R.; Feldman, P. L. Nitric oxide: A new paradigm for second messengers. J. Med. Chem., 1995, 38, 4343-4362.
2. Al-Sadoni, H. H.; Ferro, A. S-Nitrosothiols: A class of nitric oxide-donor drugs. Clin. Sci., 2000, 98, 507-520. (Pubitemid 30260999)
3. Daff, S. NO synthase: Structures and mechanisms. Nitric Oxide, 2010, 23, 1-11.
4. Gutierrez, F. R. S.; Mineo, T. W. P.; Pavanelli, W. R.; Guedes, P. M. M.; Silva, J. S. The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem. Inst. Oswaldo Cruz, 2009, 104, 236-245.
5. Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: Structure, function and inhibition. Biochem. J., 2001, 357, 593-615. (Pubitemid 32735142)
6. Stankevicius, E.; Kvelaitis, E.; Vainorius, E.; Simonsen, U. Role of nitric oxide and other endothelium-derived factors. Medicina, 2003, 39, 333-341.
7. Nitric Oxide: Biology and Chemistry: Http://www.elsevier.com/wps/find/ journaldescription.cws-home/622926/description#description (Accessed Feb 06, 2011).
8. The Open Nitric Oxide Journal: Http://www.benthamscience.com/open/tonoj/ (Accessed Feb 06, 2011).
9. Stuart-Smith, K. Demystified⋯nitric oxide. Mol. Pathol., 2002, 55, 360-366.
10. Moncada, S. Adventures in vascular biology: A tale of two mediators. Philos. Trans. R. Soc. B, 2006, 361, 735-759. (Pubitemid 44858917)
11. Furchgott, R. F.; Zawadzki, J. V. The obligatory of endothelial in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-376. (Pubitemid 11169009)
12. Palmer, R. M. J.; Ferrige, A. G.; Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 1987, 327, 524-526. (Pubitemid 17085822)
13. Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E. Chaudhuri. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U. S. A., 1987, 84, 9265-9269.
14. Green, I. C.; Chabrier, P. Nitric oxide: From basic research to clinical applications. Drug Discov. Today, 1999, 4, 47-49. (Pubitemid 29295383)
15. Gasco, A.; Fruttero, R.; Rolando, B. Focus on recent approaches for the development of new NO-donors. Mini-Rev. Med. Chem., 2005, 5, 217-229. (Pubitemid 40305733)
16. Calatayud, S.; Barrachina, D.; Esplugues, J. V. Nitric Oxide: Relation to Integrity, Injury, and Healing of the Gastric Mucosa. Microsc. Res. Tech., 2001, 53, 325-335. (Pubitemid 32494582)
17. Andrew, P. J.; Mayer, B. Enzymatic function of nitric oxide synthases. Cardiovasc. Res., 1999, 43, 521-531. (Pubitemid 29369251)
18. Murad, F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci. Rep., 1999, 19, 453-474.
19. Miller, M. R.; Megson, I. L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol., 2007, 151, 305-321. (Pubitemid 46842668)
20. Schmidt, H. H. H. W.; Walter, U. NO at Work. Cell, 1994, 78, 919-925. (Pubitemid 24292320)
21. Tsikas, D. A critical review and discussion of analytical methods in the Larginine/nitric oxide area of basic and clinical research. Anal. Biochem., 2008, 379, 139-163.
22. Friebe, A.; Koesling, D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res., 2003, 93, 96-105. (Pubitemid 36919696)
23. Gooden, D. M.; Chakrapani, H.; Toone, E. J. C-nitroso compounds: Synthesis, physicochemical properties and biological activities. Curr. Top. Med. Chem., 2005, 5, 687-705. (Pubitemid 41179728)
24. Scatena, R.; Bottoni, P.; Pontoglio, A.; Giardina, B. Pharmacological modulation of nitric oxide release: New pharmacological perspectives, potential benefits and risks. Curr. Med. Chem., 2010, 17, 61-73.
25. Gasco, A.; Fruttero, R.; Sorba, G.; Di Stilo, A.; Calvino, R. NO donors: Focus on furoxan derivatives. Pure Appl. Chem., 2004, 76, 973-981.
26. Klemenska E., Bersewicz A. Bioactivation of organic nitrates and the mechanism of nitrate tolerance. Cardiol. J., 2009, 16, 11-19.
27. Al-Sadoni, H. H.; Ferro, A. S-Nitrosothiols as Nitric Oxide-Donors: Chemistry, biology and possible future therapeutic applications. Curr. Med. Chem., 2004, 11, 2679-2690. (Pubitemid 39255556)
28. Cerecetto, H.; Porcal, W. Pharmacological Properties of Furoxans and Benzofuroxans: Recent Developments. Mini-Rev. Med. Chem., 2005, 5, 57-71. (Pubitemid 40136481)
29. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651. (Pubitemid 38981718)
30. Burgaud, J.; Ongini, E.; Soldato, P. D. Nitric oxide-releasing drugs: A novel class of effective and safe therapeutic agents. Ann. N.Y. Acad. Sci., 2002, 962, 360-371. (Pubitemid 34592324)
31. Low, S. Y. Application of pharmaceuticals to nitric oxide. Mol Aspects Med., 2005, 26, 97-138. (Pubitemid 40250166)
32. Ignarro, L. J.; Napoli, C.; Loscalzo, J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. Circ. Res., 2002, 90, 21-28. (Pubitemid 34074604)
33. Liu, V. W. T.; Huang, P.L. Cardiovascular roles of nitric oxide: A review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc. Res., 2008, 77, 19-29. (Pubitemid 351195168)
34. Tsutsui, M.; Shimokawa, H.; Otsuji, Y.; Yanagihara, N. Pathophysiological relevance of NO signaling in the cardiovascular system: Novel insight from mice lacking all NO synthases. Pharmacol. Ther., 2010, 128, 499-508.
35. Ziolo, M. T.; Kohr, M.J.; Wang, H. Nitric oxide signaling and regulation of myocardial function. J. Mol. Cell. Cardiol., 2008, 45, 625-632.
36. Funakoshi, H.; Kubota, T.; Machida, Y.; Kawamura, N.; Feldman, A.; Tsutsui, H.; Shimokawa, H.; Takeshita, A. Involvement of inducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor-α. Am. J. Physiol. Heart Circ. Physiol., 2002, 282, H2159-H2166. (Pubitemid 34663026)
37. Martelli, A.; Rapposelli, S.; Calderone, V. NO-releasing hybrids cardiovascular drugs. Curr. Med. Chem., 2006, 13, 609-625.
38. Feelisch M.; Schcinafingert, K.; Noack, E. Thiol-mediated generation of nitric oxide accounts for the vasodilator actions of furoxans. Biochem. Pharmacol., 1992, 44, 1149-1157.
39. Jia, L.; Wu, C.; Guo, W.; Young, X. Antiangiogenic effects of Snitrosocaptopril crystals as a nitric oxide donor. Eur. J. Pharmacol., 2000, 391, 137-144. (Pubitemid 30138090)
40. Tsui, D. Y. Y.; Gambino, A.; Wanstall, J. C. S-nitrosocaptopril: In vitro characterization of pulmonary vascular effects in rats. Br. J. Pharmacol., 2003, 138, 855-864. (Pubitemid 36390642)
41. Shi, L.; Mao, C.; Xu, Z.; Zhang, L. Angiotensin-converting enzymes and drug discovery in cardiovascular disease. Drug Discov. Today, 2010, 15, 332-341.
42. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy. J. Med. Chem., 1996, 39, 625-656. (Pubitemid 26069685)
43. Breschi, M. C.; Calderone, V.; Digiacomo, M.; Martelli, A.; Martinotti, E.; Minutolo, F.; Rapposelli, S.; Balsamo, A. NO-sartans: A new class of pharmacodynamic hybrids as cardiovascular drugs. J. Med. Chem., 2004, 47, 5597-5600. (Pubitemid 39447253)
44. Breschi, M. C.; Calderone, V.; Digiacomo, M.; Macchia, M.; Martelli, A.; Martinotti, E.; Minutolo, F.; Rapposelli, S.; Rossello, A.; Testai, L; Balsamo, A. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: Design, synthesis, and biopharmacological properties. J. Med. Chem., 2006, 49, 2628-2639.
45. Dhein S.; Salameh, A.; Berkels, R.; Klaus, W. Dual mode of action of dihydropyridine calcium antagonists. A role for nitric oxide. Drugs, 1999, 58, 397-404. (Pubitemid 29427851)
46. Stilo, A.; Visentin, S.; Cena, C.; Gasco, A. M.; Ermondi, G.; Gasco, A. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. J. Med. Chem., 1998, 41, 5393-5401. (Pubitemid 29031323)
47. Fruttero, R.; Boschi, D.; Stilo, A.; Gasco, A. The furoxan system as a useful tool for balancing "hybrids" with mixed α1-antagonist and NO-like vasodilator activities. J. Med. Chem., 1995, 38, 4944-4949.
48. Boschi, D.; Stilo, A.; Cena, C.; Lolli, M.; Fruttero, R.; Gasco, A. Studies on agents with mixed NO-dependent vasodilating and β-blocking activities. Pharm. Res., 1997, 14, 1750-1758. (Pubitemid 28062921)
49. Wallace, J. L.; Ignarro, L. J.; Fiorucci, S. Potential cardioprotective actions of NO-releasing aspirin. Nat. Rev. Drug Discov., 2002, 1, 375-382. (Pubitemid 37361467)
50. Shaw, C. A.; Taylor, E. L.; Megson, I. L.; Rossi, A. G. Nitric oxide and the resolution of inflammation: Implications for atherosclerosis. Mem. Inst. Oswaldo Cruz, 2005, 100, 67-71. (Pubitemid 40685442)
51. Keeble, J. E.; Moore, P. K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol., 2002, 137, 295-310.
52. Muscara, M. N.; Lovren F.; McKnight W.; Dicay M.; Soldato P.; Triggle C. R.; Wallace J. L. Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br. J. Pharmacol., 2001, 133, 1314-1322. (Pubitemid 32783492)
53. Ongini, E.; Impagnatiello, F.; Bonazzi, A.; Guzzetta, M.; Govoni, M.; Monopoli, A.; Soldato, P. D.; Ignarro, L. Nitric oxide (NO)-releasing statin derivates, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 8497-8502. (Pubitemid 38736603)
54. Halen, P. K.; Murumkar, P. R.; Giridhar, R.; Yadav, M. R. Prodrug designing of NSAIDs. Mini-Rev. Med. Chem., 2009, 9, 124-139.
55. Matsui, H.; Shimokawa, O.; Kaneko, T.; Nagano, Y.; Rai, K.; Hyodo, I. The pathophysiology of non-steroidal anti-inflamatory drug (NSAID) induced mucosal injuries in stomach and small intestine. J. Clin. Biochem. Nutr., 2011, 48, 107-111.
56. Meade, T. W.; Roderick, P. J.; Brennan, P. J.; Wilkes, H. C.; Kelleher, C. C. Extracranial bleeding and others symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb. Haemost., 1992, 68, 1-6.
57. Fiorucci, S.; Antonelli, E. NO-NSAIDs: From inflammatory mediators to clinical readouts. Inflamm. Allergy Drug Targets, 2006, 5, 121-131. (Pubitemid 43796674)
58. Koç, A. E.; Kuçukguzel, S. G. Medicinal chemistry and anti-inflammatory activity of nitric oxide-releasing NSAI drugs. Mini-Rev. Med. Chem., 2009, 9, 611-619.
59. Bandarage, U. K.; Janero, D. R. Nitric oxide-releasing nonsteroidal antiinflammatory drugs: Novel grastrointestinal-sparing drugs. Mini-Rev. Med. Chem., 2001, 1, 57-70.
60. Lanas, A. Cyclo-oxygenase-1/cyclo-oxygenase-2 non-selective non-steroidal anti-inflammatory drugs: Epidemiology of gastrointestinal events. Digest. Liver Dis., 2001, 33, S29-S34. (Pubitemid 34041478)
61. Chiroli, V.; Benedini, F.; Ongini, E.; Soldato, P. D. Nitric oxide-donating non-steroidal anti-inflammatory drugs: The case of nitroderivates of aspirin. Eur. J. Med. Chem., 2003, 38, 441-446. (Pubitemid 36577196)
62. Gilmer, J. F.; Moriarty, L. M.; Clancy, J. M. Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirin. Bioorg. Med. Chem. Lett., 2007, 17, 3217-3220. (Pubitemid 46702601)
63. Cena, C.; Lolli, M. L.; Lazzarato, L.; Guaita, E.; Morini, G.; Coruzzi, G.; Mcelroy, S. P.; Megson, I. L.; Fruttero, R.; Gasco, A. Antiinflammatory, gastrosparing and antiplatelet properties of new NO-donor ester of aspirin. J. Med. Chem., 2003, 46, 747-754. (Pubitemid 36258866)
64. Turnbull, C. M.; Cena, C.; Fruttero, R.; Gasco, A.; Rossi, A. G.; Megson, I. L. Mechanism of action of novel NO-releasing furoxan derivates of aspirin in human platelets. Br. J. Pharmacol., 2006, 148, 517-526. (Pubitemid 43882088)
65. Turnbull, C. M.; Marcarino, P.; Sheldrake, T. A.; Lazzarato, L.; Cena, C.; Fruttero, R.; Gasco, A.; Fox, S.; Megson, I. L.; Rossi, A. G. A novel hybrid aspirin-NO-releasing compound inhibits TNF-alpha release from LPSactivated human monocytes and macrophages. J. Inflamm. (London), 2008, 5, 1-10.
66. Fiorucci, S.; Santucci, L.; Cirino, G.; Mencarelli, A.; Familiari, L.; Soldato, P. D. IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: New insights in the antiinflammatory mechanism of nitric oxidereleasing nonsteroidal antiinflammatory drugs. J. Immunol., 2000, 165, 5245-5254.
67. Dimmeler, S.; Haendeler, J.; Nehls, M.; Zeiher, A. M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp. Med., 1997, 185, 601-607. (Pubitemid 27098145)
68. Lazzarato, L.; Donnola, M.; Rolando, B.; Marini, E.; Cena, C.; Coruzzi, G.; Guaita, E.; Morini, G.; Fruttero, R.; Gasco, A.; Biondi, S.; Ongini, E. Searching for new NO-donor aspirin-like molecule: A new class of nitrooxyacyl derivates of salicylic acid. J. Med. Chem., 2008, 51, 1894-1903. (Pubitemid 351438871)
69. Lazzarato, Donnola, M.; Rolando, B.; Chegaev, K.; Marini, E.; Cena, C.; Stilo, D. A.; Fruttero, R.; Biondi, S.; Ongini, E.; Gasco, A. (Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. J. Med. Chem., 2009, 52, 5058-5068.
70. Velazquez, C. A.; Chen, Q. H.; Citro, M. L.; Keefer, L. K.; Knaus, E. E. Second-generation aspirin and indomethacin prodrugs possessing an O2- (acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem., 2008, 51, 1954-1961. (Pubitemid 351438876)
71. Bandarage, U. K.; Chen, L.; Fang, X.; Garvey, D. S.; Glavin, A.; Janero, D. R.; Letts, L. G.; Mercer, G. J.; Saha, J. K.; Schroeder, J. D.; Shumway, M. J.; Tam, S. W. Nitrosothiol esters of diclofenac: Synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem., 2000, 43, 4005-4016.
72. Carvalho, P. S.; Maróstica, M.; Gambero, A.; Pedrazzoli, J. Synthesis and pharmacological characterization of a novel nitric oxide-releasing diclofenac derivate containing a benzofuroxan moiety. Eur. J. Med. Chem., 2010, 45, 2489-2493.
73. Nemmani, K. V. S.; Mali, S. V.; Borhade, N.; Pathan, A. R.; Karwa, M.; Pamidiboina, V.; Senthilkumar, S. P.; Gund, M.; Jain, A. K.; Mangu, N. K.; Dubash, N. P.; Desai, D. C.; Sharma, S.; Satyam, A. NO-NSAIDs: Gastricsparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs. Bioorg. Med. Chem. Lett., 2009, 19, 5297-5301.
74. Gaitan, G.; Ahuir, J.; Soldato, P. D.; Herrero, J. F. Comparison of the antinociceptive activity of two new NO-reieasing derivatives of the NSAID S-ketoprofen in rats. Br. J. Pharmacol., 2004, 143, 533-540. (Pubitemid 39524270)
75. Fiorucci, S.; Antonelli, E.; Mencarelli, A.; Palazzetti, B.; Alvarez-Miller, L.; Muscara, M.; Soldato, P. D.; Sanpaolo, L.; Wallace, J. L.; Morelli, A. A NOreleasing derivate of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br. J. Pharmacol., 2002, 135, 589-599. (Pubitemid 34177636)
76. Engelhardt, F. C.; Shi, Y.; Cowden, C. J.; Conlon, D. A.; Pipik, B.; Zhou, G.; Mcnamara, J. M.; Dolling, U. Synthesis of a NO-releasing prodrug of rofecoxib. J. Org. Chem., 2006, 71, 480-491. (Pubitemid 43100735)
77. Ongini, E.; Bolla, M. Nitric-oxide based nonsteroidal anti-inflammatory agents. Drug Discov. Today Ther. Strateg., 2006, 3, 395-400. (Pubitemid 44774490)
78. Abdellatif, K. R. A.; Chowdhury, M. A.; Velazquez, C. A.; Huang, Z.; Dong, Y.; Das, D.; Yu, G.; Suresh, M. R.; Knaus, E. E. Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Synthesis, biological evaluation and nitric oxide release studies. Bioorg. Med. Chem. Lett., 2010, 20, 4544-4549.
79. Coulter, J. A.; Mccarthy, H. O.; Xiang, J.; Roedl, W.; Wagner, E.; Robson, T.; Hirst, D. G. Nitric oxide - A novel therapeutic for cancer. Nitric Oxide, 2008, 19, 192-198.
80. Weigert, A.; Brüne, B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide, 2008, 19, 95-102.
81. Iyer, A. K. V.; Azad, N.; Wangb, L.; Rojanasakul, Y. Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide, 2008, 19, 146-151.
82. Fitzpatrick, B.; Mehibel, M.; Cowen, R. L.; Stratford, I. J. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide, 2008, 19, 217-224.
83. Wink, D. A.; Ridnour, L. A.; Hussain, S. P.; Harris, C. C. The reemergence of nitric oxide and cancer. Nitric Oxide, 2008, 19, 65-67. (Pubitemid 351970245)
84. É, J.; De La Mata, M. Nitric oxide and cancer. World J. Hepatol., 2010, 2, 337-344.
85. Naimi, E.; Zhou, A.; Khalili, P.; Wiebe, L. I.; Balzarini, J.; Clercq, E.; Knaus, E. E. Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents. J. Med. Chem., 2003, 46, 995-1004. (Pubitemid 36423146)
86. Sorensen, H. T.; Friis, S.; Norgard, B.; Mellemkjaer, L.; Blot, W. J.; McLaughlin, J. K.; Ekbom, A.; Baron, J. A. Risk of cancer in a large cohort of nonaspirin NSAID users: A population-based study. Br. J. Cancer, 2003, 88, 1687-1692. (Pubitemid 36760410)
87. Lai, Y.; Shen, L.; Zhang, Z.; Liu, W.; Zhang , Y.; Ji, H.; Tian, J. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents. Bioorg. Med. Chem. Lett., 2010, 20, 6416-6420.
88. Ling, Y.; Ye, X.; Ji, H.; Zhang, Y.; Lai, Y.; Peng, S.; Tian, J. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. Bioorg. Med. Chem., 2010, 18, 3448-3456.
89. Corley, D. A.; Kerlikowske, K.; Verma, R.; Buffler, P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and metaanalysis. Gastroenterology, 2003, 124, 47-56. (Pubitemid 36055338)
90. Tesei, A.; Zoli, W.; Fabbri, F.; Leonetti, C.; Rosetti, M.; Bolla, M.; Amadori, D.; Silvestrini, R. NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. Nitric Oxide, 2008, 19, 225-236.
91. Hulsman, N.; Medema, J. P.; Bos, C.; Jongejan, A.; Leurs, R.; Smit, M. J.; Esch, I. J. P.; Richel, D.; Wijtmans, M. Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem., 2007, 50, 2424-2431. (Pubitemid 46799254)
92. Chen, C.; Shi, Y. Q.; Song, J.; Qi, Q. S.; Gu, L.; Wang, P. G. Delivery of nitric oxide released from β-gal-NONOate activation by β-galactosidase and its activity against Escherichia coli. Biol. Pharm. Bull., 2006, 29, 1239-1241. (Pubitemid 43845490)
93. Long, R.; Light, B.; Talbot, J. A. Mycobacteriocidal action of exogenous nitric oxide. Antimicrob. Agents Chemother., 1999, 43, 403-405. (Pubitemid 29079185)
94. Hetrick, E. M.; Shin, J. H.; Stasko, N. A.; Johnson, C. B.; Wespe, D. A.; Holmuhamedov, E. Schoenfisch, M. H. Bactericidal efficacy of nitric oxidereleasing silica nanoparticles. ACS Nano, 2008, 2, 235-246. (Pubitemid 351585938)
95. Hosogi, S.; Iwasaki, Y.; Yamada, T.; Komatani-Tamiya, N.; Hiramatsu, A.; Kohno, Y.; Ueda, M.; Arimoto, T.; Marunaka, Y. Effect of inducible nitric oxide synthase on apoptosis in Candida albicans-induced acute lung injury. Biomed. Res., 2008, 29, 257-266.
96. Konter, J.; Mollmann, U.; Lehmann, J. NO-donors. Part 171: Synthesis and antimicrobial activity of novel ketoconazole-NO-donor hybrid compounds. Bioorg. Med. Chem., 2008, 16, 8294-8300.
97. Colasanti, M.; Persichini, T.; Venturini, G.; Ascenzi, P. S-nitrosylation of viral proteins: Molecular bases for antiviral effect of nitric oxide. IUBMB Life, 1999, 48, 25-31. (Pubitemid 29512981)
98. Keyaerts, E.; Vijgen, L.; Chen, L.; Maes, P.; Hedenstierna, G.; Ranst, M. V. Inhibition of SARS-coronavirus infection in vitro by S-nitroso- Nacetylpenicillamine, a nitric oxide donor compound. Int. J. Infect. Dis., 2004, 8, 223-226. (Pubitemid 38953677)
99. Takhampunya, R.; Padmanabhan, R.; Ubol, S. Antiviral action of nitric oxide on dengue virus type 2 replication. J. Gen. Virol., 2006, 87, 3003-3011. (Pubitemid 44463909)
100. Fostera, M. W.; Forresterb, M. T.; Stamlera, J. S. A protein microarray-based analysis of S-nitrosylation. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 18948-18953.
101. Acosta, F.; Real, F.; Galarreta, C. M. R.; Diaz, R.; Padilla, D.; Ellis, A. E. Toxicity of nitric oxide and peroxynitrite to Photobacterium damselae subsp. piscicida. Fish Shellfish Immunol., 2003, 15, 241-248. (Pubitemid 36990185)
102. Privett, B. J.; Deupree, S. M.; Backlund, C. J.; Rao, K. S.; Johnson, C. B.; Coneski, P. N.; Schoenfisch, M. H. Synergy of nitric oxide and silver sulfadiazine against gram-negative, gram-positive, and antibiotic-resistant pathogens. Mol. Pharm., 2010, 7, 2289-2296.
103. Cole, S. P.; Kharitonov, V. F.; Guiney, D. G. Effect of nitric oxide on Helicobacter pylori morphology. J. Infect. Dis., 1999, 180, 1713-1717. (Pubitemid 29506481)
104. Bertinaria, M.; Galli, U.; Sorba, G.; Fruttero, R.; Gasco, A.; Brenciaglia, M. I.; Scaltrito, M. M.; Dubini, F. Synthesis and anti- Helicobacter pylori properties of NO-donor/metronidazole hybrids and related compounds. Drug Dev. Res., 2003, 60, 225-239. (Pubitemid 37351794)
105. Privett, B. J.; Nutz, S. T.; Schoenfisch, M. H. Efficacy of surface-generated nitric oxide against Candida albicans adhesion and biofilm formation. Biofouling, 2010, 26, 973-983.
106. Carpenter, A. W.; Slomberg, D. L.; Rao, K. S.; Schoenfisch, M. H. Influence of scaffold size on bactericidal activity of nitric oxide- releasing silica nanoparticles. ACS Nano, 2011, 5, 7235-7244.
107. Marcinkiewicz, J. Nitric oxide and antimicrobial activity of reactive oxygen intermediates. Immunopharmacology, 1997, 37, 35-41. (Pubitemid 27339018)
108. Klink, M.; Cedzynski, M.; Swierzko, A. S.; Tchorzewski, H.; Sulowska, Z. Involvement of nitric oxide donor compounds in the bactericidal activity of human neutrophils in vitro. J. Med. Microbiol., 2003, 52, 303-308. (Pubitemid 36515291)
109. Mcelhaney-Feser, G. E.; Raulli, R. E.; Cihlar, R. L. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob. Agents Chemother., 1998, 42, 2342-2346. (Pubitemid 28420375)
110. Brunet, L. R. Nitric oxide in parasitic infections. Int. Immunopharmacol., 2001, 1, 1457-1467. (Pubitemid 32622790)
111. Durand, J. L.; Mukherjee, S.; Commodari, F. Souza, A. P.; Zhao, D.; Machado, F. S.; Tanowitz, H. B.; Jelicks, L. A. Role of NO synthase in the development of Trypanosoma cruzi-induced cardiomyopathy in mice. Am. J. Trop. Med. Hyg., 2009, 80, 782-787.
112. Venturini, G.; Fioravanti, E.; Colasanti, M.; Persichini, T.; Ascenzi, P. Cys25-nitrosylation inactives papain. Biochem. Mol. Biol. Int., 1998, 46, 425-428.
113. Venturini, G.; Salvati, L.; Muolo, M.; Colasanti, M.; Gradoni, L.; Ascenzi, P. Nitric oxide inhibits cruzipain, the major papain-like cysteine proteinase from Trypanosoma cruzi. Biochem. Biophys. Res. Commun., 2000, 270, 437-441. (Pubitemid 30446854)
114. Colasanti, M.; Salvati, L.; Venturini, G.; Ascenzi, P.; Gradoni, L. Cysteine protease as a target for nitric oxide in parasitic organisms. Trends Parasitol., 2001, 17, 575. (Pubitemid 34088115)
115. Rockett, K. A.; Awburn, M. M.; Cowden, W. B.; Clark, I. A. Killing of plasmodium falciparum in vitro by nitric oxide derivates. Infect. Immun., 1991, 59, 3280-3283.
116. Sanchez-Delgado, R. A.; Lazardi, K.; Rincon, L.; Urbina, J. A. Toward a novel metal-based chemothetapy against tropical disease. 1. Enhancement of the efficacy of clotrimazole against Trypanossoma cruzi by complexation to ruthenium in RuCl2(clotrimazole)2. J. Med. Chem., 1993, 36, 2041-2043. (Pubitemid 23230336)
117. Silva, J. J. N.; Osakabe, A. L.; Pavanelli, W. R.; Silva, J. S.; Franco, D. W. In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors. Br. J. Pharmacol., 2007, 152, 112-121. (Pubitemid 47339905)
118. Guedes, P. M. M.; Oliveira, F. S.; Gutierrez, F. R. S.; Silva G. K.; Rodrigues, G. J.; Bendhack, L. M.; Franco, D. W.; Mattas, M. A. V; Zamboni, D. S.; Silva, R. S.; Silva, J. S. Nitric oxide donor trans-[RuCl([15]aneN4)NO]2 as a possible therapeutic approach for Chagas̀ disease. Br. J. Pharmacol., 2010, 160, 258-269.
119. Silva, J. J. N.; Guedes, P. M. M.; Zottis, A.; Balliano, T. L.; Silva, F. O. N.; Lopes, L. G. F.; Ellena, J.; Oliva, G.; Andricopulo, A. D.; Franco, D. W.; Silva, J. S. Novel ruthenium complexes as potential drugs for Chagas̀s disease: Enzyme inhibition and in vitro/in vivo trypanocidal activity. Br. J. Pharmacol., 2010, 160, 260-269.
120. James, S. L. Role of Nitric oxide in parasitic infections. Microbiol. Rev., 1995, 59, 533-547.
121. Gazi, U.; Martinez-Pomares, L. Influence of the mannose receptor in host immune responses. Immunobiology, 2009, 214, 554-561.
122. Valdez, C. A.; Saavedra, J. E.; Showalter, B. M.; Davies, K. M.; Wilde, T. C.; Citro, M. L.; Barchi, J. J.; Deschamps, J. R.; Parrish, D.; El-Gayar, S.; Schleicher, U.; Bogdan, C.; Keefer, L. K. Hydrolytic reactivity trends among potential prodrugs of the O2-glycosylated diazeniumdiolate family. Targeting nitric oxide to macrophages for antileishmanial activity. J. Med. Chem., 2008, 51, 3961-3970. (Pubitemid 351956524)
123. Nahrevanian, H.; Najafzadeh, M.; Hajihosseini, R.; Nazem, H.; Farahmand, M.; Zamani, Z. Anti-leishmania effects of trinitroglycerin in BALBC/C mice infected with Leishmania major via nitric oxide pathway. Korean J. Parasitol., 2009, 47, 109-115.
124. Sadanand, S. Malaria: An evaluation of the current state of research on pathogenesis and antimalarial. Yale J. Biol. Med., 2010, 83, 185-191.
125. Burrows, J. N.; Chibale, K.; Wells, T. N. The state of the art in anti-malarial drug discovery and development. Curr. Top. Med Chem., 2011, 11, 1226-1254.
126. Petersen, I., Eastman, R.; Lanzer, M. Drug resistant malaria: Molecular mechanisms and implications for public health. FEBS lett., 2011, 585, 1551-1562.
127. Galli, U.; Lazzarato, L.; Bertinaria, M. Sorba, G.; Gasco, A.; Parapini, S.; Taramelli, D. Synthesis and antimalarial activities of some furoxan sulfones and related furazans. Eur. J. Med. Chem., 2010, 40, 1335-1340. (Pubitemid 41618275)
128. Bertinaria, M.; Guglielmo, S.; Rolando, B.; Giorgis, M.; Aragno, C.; Fruttero, R.; Gasco, A.; Parapini, S.; Taramelli, D.; Martins, Y. C.; Carvalho, L. J. M. Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. Eur. J. Med. Chem., 2011, 46, 1757-1767.
129. Mckerrow, J. H.; Engel, J. C.; Caffrey, C. R. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem., 1999, 7, 639-644. (Pubitemid 29150307)
130. Ascenzi, P.; Bocedi, A.; Gentile, M.; Visca, P.; Gradoni, L. Inactivation of parasite cysteine proteinases by the NO-donor 4-(phenylsulfonyl)-3-((2- (dimethylamino)ethyl)thio)-furoxan oxalate. Biochim. Biophys. Acta, 2004, 1703, 69-77. (Pubitemid 39575075)
131. Koss, M. C. Functional role of nitric oxide in regulation of ocular blood flow. Eur. J. Pharmacol., 1999, 374, 161-174. (Pubitemid 29287131)
132. Goldstein, I. M.; Otswaldp, P.; Roth, S. Nitric oxide: A review of its role in retinal function and disease. Vision Res., 1996, 36, 2979-2994. (Pubitemid 26326608)
133. Khoobehi, B.; Chiroli, V.; Ronchetti, D.; Miglietta, D.; Thompson, H.; Ongini, E.; Impagnatiello, F. Enhanced oxygen saturation in optic nerve head of non-human primate eyes following the intravitreal injection of NCX 434, an innovative nitric oxide-donating glucocorticoid. J. Ocul. Pharmacol. Ther., 2011, 27, 115-121.
134. Galassi, F.; Masini, E.; Gianbene, B.; Fabrizi, F.; Uliva, C.; Bolla, M.; Ongini, E. A topical nitric oxide-releasing dexamethasone derivate: Effects on intraocular pressure and ocular haemodynamics in a rabbit glaucoma model. Br. J. Ophthalmol., 2006, 90, 1414-1419. (Pubitemid 44702072)
135. Borgui, V.; Bastia, E.; Guzzetta, M.; Chiroli, V.; Toris, C. B.; Batugo, M. R.; Carreiro, S. T.; Chong, W. K. M.; Gale, D. C.; Kucera, D. J.; Jia, L.; Prasanna, G.; Ongini, E.; Krauss, A. H. P.; Impagnatiello, F. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J. Ocul. Pharmacol. Ther., 2010, 26, 125-132.
136. Impagnatiello, F.; Borgui, V.; Gale, D. C.; Batugo, M.; Guzzetta, M.; Brambilla, S.; Carreiro, S. T.; Chong, W. K. M.; Prasanna, G.; Chiroli, V.; Ongini, E.; Krauss, A. H. P. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs. Exp. Eye Res., 2011, 93, 243-249.
137. Mincione, F.; Benedini, F.; Biondi, S.; Cecchi, A.; Temperini, C.; Formicola, G.; Pacileo, I.; Scozzafava, A.; Masini, E.; Supuran, C. T. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg. Med. Chem. Lett., 2011, 21, 3216-3221.
138. Steele, R. M.; Benedini, F.; Biondi, S.; Borghi, V.; Carzaniga, L.; Impagnatiello, F.; Miglietta, D.; Chong, W. K. M.; Rajapakse, R.; Cecchi, A.; Temperini, C.; Supuran, C. T. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg. Med. Chem. Lett., 2009, 19, 6565-6570.
139. Hobbs, A. J.; Higgs, A.; Moncada, S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 191-220. (Pubitemid 29222557)
140. Rehni, A. K.; Singh, T. G.; Kalra, R.; Singh, N. Pharmacological inhibition of inducible nitric oxide synthase attenuates the development of seizures in mice. Nitric Oxide, 2009, 21, 120-125.
141. Kavya, R.; Saluja, R.; Singh, S.; Dikshit, M. Nitric oxide synthase regulation and diversity: Implications in Parkinsoǹs disease. Nitric Oxide, 2006, 15, 280-294. (Pubitemid 44647899)
142. Zheng, B.; Zheng, T.; Wang, L.; Chen, X.; Shi, C.; Zhao, S. Aminoguanidine inhibition of iNOS activity ameliorates cerebral vasospasm after subarachnoid hemorrhage in rabbits via restoration of dysfunctional endothelial cells. J. Neurol. Sci., 2010, 295, 97-103.
143. Ricciardolo, F. L. M.; Nijkamp, F. P.; Folkerts, G. Nitric oxide synthase (NOS) as therapeutic target for asthma and chronic obstructive pulmonary disease. Curr. Drug Targets, 2006, 7, 721-735. (Pubitemid 43827268)
144. Vallance, P.; Leiper, J. Blocking NO synthesis: How, where and why? Nat. Rev. Drug Discov., 2002, 1, 939-950. (Pubitemid 37361600)
145. Paige, J.; Jaffrey, S. R. Pharmacologic manipulation of nitric oxide signaling: Targeting NOS dimerization and protein-protein interactions. Curr. Topics Med. Chem., 2007, 7, 97-114. (Pubitemid 46062399)
146. Groves, J. T.; Wang, C. C. Y. Nitric oxide synthase: Models and mechanism. Curr. Opin. Chem. Biol., 2000, 4, 687-695.
147. Hagmann, W. K.; Caldwell, C. G.; Chen, P. L.; Durette, P. L.; Esser, C. K.; Lanza, T. J.; Kopka, I. E.; Guthikonda R.; Shah, S. K.; Maccoss, M.; Chabin, R. M.; Fletcher, D.; Grant, S. K.; Green, B. G.; Humes, J. L.; Kelly, T. M.; Luell, S.; Meurer, R.; Moore, V.; Pacholok, S. G.; Pavia, T.; Williams, H. R.; Wong, K. K. Substituted 2-aminopyridines as inhibitors of nitric oxide synthases. Bioorg. Med. Chem., 2000, 10, 1975-1978. (Pubitemid 30663353)
148. Connolly, S.; Aberg, A.; Arvai, A.; Beaton, H. G.; Cheshire, D. R.; Cook, A. R.; Cooper, S.; Cox, D.; Hamley, P.; Mallinder, P.; Millichip, I.; Nicholls, D. J.; Rosenfeld, R. J.; St-Gallay, S. A.; Tainer, J.; Tinker, A. C.; Wallace, A. V. 2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution. J. Med. Chem., 2004, 47, 3320-3323. (Pubitemid 38702724)
149. Tinker, A. C.; Beaton, H. G.; Boughton-Smith, N.; Cook, T. R.; Cooper, S. L.; Fraser-Rae, L.; Hallam, K.; Hamley, P.; Mcinally, T. Nicholls, D. J.; Pimm, A. D.; Wallace, A. V. 1,2-dihydro-4-quinazolinamines:potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo. J. Med. Chem., 2003, 46, 913-916. (Pubitemid 36423137)
150. Garcin, E. D.; Arvai, A. S.; Rosenfeld, R. J.; Kroeger, M. D.; Crane, B. R.; Andersson, G.; Andrews, G.; Hamley, P. J.; Mallinder, P. R.; Nicholls, D. J.; St-Gallay, S. A.; Tinker, A. C.; Gensmantel, N. P.; Mete, A.; Cheshire, D. R.; Connolly, S.; Stuehr, D. J.; Aberg, A.; Wallace, A. V.; Tainer, J. A.; Getzoff, E. D. Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat. Chem. Biol., 2008, 4, 700-707.
151. Maccallini, C.; Patruno, A.; Lannutti, F.; Ammazzalorso, A.; Filippis, B. D.; Fantacuzzi, M.; Franceschelli, S.; Giampietro, L.; Masella, S.; Felaco, M.; Re, N.; Amoroso, R. N-substituted acetamidine and 2-methylimidazole derivates as selective inhibitors of neuronal nitric oxide synthase. Bioorg. Med. Chem. Lett., 2010, 20, 6495-6499.
152. Silverman, R. B. Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases. Acc. Chem. Res., 2009, 42, 439-451.
153. Delker, S. L.; Ji, H.; Li, H.; Jamal, J.; Fang, J.; Xue, F.; Silverman, R. B.; Poulos, T. L. Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of cerebral palsy. J. Am. Chem. Soc., 2010, 132, 5437-5442.
154. Lawton, G. R.; Ranaivo, H. R.; Wing, L. K.; Ji, H.; Xue, F.; Martesek, P.; Roman, L. J.; Watterson, D. M.; Silverman, R. B. Analogues of 2- aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorg. Med. Chem., 2009, 17, 2371-2380.
155. Xue, F.; Fang, J.; Delker, S. L.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase. J. Med. Chem., 2011, 54, 2039-2048.
156. Delker, S. L.; Xue, F.; Li, H.; Jamal, J.; Silverman, R. B.; Poulos, T. L. Role of zinc in isoform-selective inhibitor binding to neuronal nitric oxide synthase. Biochemistry, 2010, 49, 10803-10810.
157. Bonnefous, C.; Payne, J. E.; Roppe, J.; Zhuang, H.; Chen, X.; Symons, K. T.; Nguyen, P. M.; Sablad, M.; Rozenkrants, N.; Zhang, Y.; Wang, L.; Severance, D.; Walsh, J. P.; Yazdani, N.; Shiau, A. K.; Noble, S. A.; Rix, P.; Rao, T. S.; Hassig, C. A.; Smith, N. D. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. J. Med. Chem., 2009, 52, 3047-3062.
158. Payne, J. E.; Bonnefous, C.; Symons, K. T.; Nguyen, P. M.; Sablad, M.; Rozenkrants, N.; Zhang, Y.; Wang, L.; Yazdani, N.; Shiau, A. K.; Noble, S. A.; Rix, P.; Rao, T. S.; Hassig, C. A.; Smith, N. D. Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1- yl)methyl)-7,8- difluoroquinolin-2(1H)-one (KD7332) part 2: Identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models. J. Med. Chem., 2010, 53, 7739-7755.
159. Calderone, V.; Rapposelli, S.; Martelli, A.; Digiacomo, M.; Testai, L.; Torri, S.; Marchetti, P.; Breschi, M. C.; Balsamo, A. NO-glibenclamide derivatives: Prototypes of a new class of nitric oxide-releasing anti-diabetic drugs. Bioorg. Med. Chem., 2009, 17, 5426-5432.
160. Bernstein, H. G.; Bogerts, B.; Keilhoff, G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res., 2005, 78, 69-86. (Pubitemid 41188326)
161. Umathe, S. N.; Bhutada, P. S.; Jain, N. S.; Mundhada, Y. R.; Borkar, S. S.; Dhumal, B. Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice. Nitric Oxide, 2009, 21, 140-147.
162. Pinto, V. L. M.; Brunini, T. M. C.; Ferraz, M. R.; Okinga, A.; Mendes- Ribeiro, A. C. Depression and cardiovascular disease: Role of nitric oxide. Cardiovasc. Hematol. Agents Med. Chem., 2008, 6, 142-149. (Pubitemid 351935021)
163. Neeb, L.; Reuter, U. Nitric Oxide in Migraine. CNS Neurol. Disord. Drug Targets, 2007, 6, 258-264. (Pubitemid 47232937)
164. Toda, N.; Imamura, T.; Okamura, T. Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. Pharmacol. Ther., 2010, 127, 189-209.
165. Cordes, C. M.; Bennett, R. G.; Siford, G. L.; Hamel, F. G. Nitric oxide inhibits insulin-degrading enzyme activity and function through Snitrosylation. Biochem. Pharmacol., 2009, 77, 1064-1073.
166. Nakano, Y.; Yoshimura, R.; Nakano, H.; Ikenouchi-Sugita, A.; Hori, H.; Umene-Nakano, W.; Ueda, N.; Nakamura, J. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: A pilot study. Hum. Psychopharmacol., 2010, 25, 139-144.